AAP
AGIO icon

Arax Advisory Partners’s Agios Pharmaceuticals AGIO Stock Holding History

Arax Advisory Partners’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$200K Buy
5,376
+5,256
+4,380% +$159K ﹤0.01% 2253
2026
Q1 		$4.06K Buy
120
+41
+52% +$1.16K ﹤0.01% 2884
2025
Q4 		$2.15K Sell
79
-623
-89% -$21.9K ﹤0.01% 3233
2025
Q3 		$28.2K Buy
702
+689
+5,300% +$25.9K ﹤0.01% 2115
2025
Q2 		$432 Sell
13
-7
-35% -$212 ﹤0.01% 2941
2025
Q1 		$586 Sell
20
-62
-76% -$2.06K ﹤0.01% 2512
2024
Q4 		$2.69K Sell
82
-34
-29% -$1.6K ﹤0.01% 1937
2024
Q3 		$5.15K Sell
116
-6
-5% -$272 ﹤0.01% 1703
2024
Q2 		$5.26K Buy
122
+108
+771% +$3.9K ﹤0.01% 1576
2024
Q1 		$409 Buy
+14
New +$375 ﹤0.01% 1245

Other funds holding AGIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Arax Advisory Partners's AGIO Position: Q2 2026 in Review

Arax Advisory Partners increased its Agios Pharmaceuticals (AGIO) stake by 4,380% in Q2 2026, buying an estimated $159K and bringing the position to 5,376 shares worth $200K. The position accounts for ﹤0.01% of the portfolio, ranked #2253.

Arax Advisory Partners first reported a position in AGIO in Q1 2024 and has held it in 10 quarters since. 238 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.

  • Arax Advisory Partners held 5,376 shares of Agios Pharmaceuticals worth $200K as of Q2 2026.
  • Arax Advisory Partners bought 5,256 Agios Pharmaceuticals shares in Q2 2026, an estimated $159K.
  • Agios Pharmaceuticals made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #2253 holding.
  • Arax Advisory Partners first reported a position in Agios Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • 238 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.